Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of rFVIIa BI for On-demand Treatment of Acute Bleeding in Hemophilia A or B with Inhibitors
2011-006294-26Phase 3Completed
- Sponsor
- Baxter International Inc.
- Start
- Feb 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of coagulation factor VIIa in hemophilia A, hemophilia B (HB) and hemophilia (2 arms), sponsored by Baxter International Inc. Primary endpoint: Primary hemostatic efficacy. Started Feb 2013; status: completed.
02
Drugs
coagulation factor VIIa
03
Conditions
hemophilia Ahemophilia B (HB)hemophilia
Beyond the preview
Go deeper on 2011-006294-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006294-26.